HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions

被引：123

作者：

Ikeda, Hiroko ^{[1
]}

Takahashi, Yukitoshi ^{[2
]}

Yamazaki, Etsuko

Fujiwara, Tateki

Kaniwa, Nahoko ^{[3
]}

Saito, Yoshiro ^{[3
]}

Aihara, Michiko ^{[3
]}

Kashiwagi, Mariko ^{[4
]}

Muramatsu, Masaaki ^{[4
]}

机构：

[1] Shizuoka Inst Epilepsy & Neurol Disorders, Natl Epilepsy Ctr, Aoi Ku, Shizuoka 4208688, Japan

[2] Gifu Univ, Sch Med, Dept Pediat, Gifu 500, Japan

[3] Natl Inst Hlth Sci, Japan Severe Adverse React Res Grp, Tokyo, Japan

[4] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Epidemiol, Chiyoda Ku, Tokyo, Japan

来源：

EPILEPSIA | 2010年 / 51卷 / 02期

关键词：

Carbamazepine; Stevens-Johnson syndrome; HILA class I; HLA-B*5901; Cutaneous adverse drug reactions; STEVENS-JOHNSON-SYNDROME;

D O I：

10.1111/j.1528-1167.2009.02269.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Carbamazepine (CBZ) is frequently used for treating epilepsy, but this drug causes cutaneous adverse drug reactions (cADRs) that may range from mild to severe. It is reported recently that the human leukocyte antigen HLA-B*1502 is associated with Stevens-Johnson syndrome (SJS) induced by CBZ in Han Chinese. We examined HLA class I in 15 Japanese patients who fulfilled the diagnostic criteria for CBZ-induced cADRs (mild in 10 and severe = SJS in 5). HLA-B*1518, HLA-B*5901 and HLA-C*0704 alleles showed higher relative risks (above 10.0) for severe cADRs. The haplotype (HLA-A*2402-B*5901-C*0102) had high relative risk (16.09) for severe cADRs. In patients with severe cADRs, frequencies of HLA-A*1101, HLA-A*3303, HLA-B*1501, HLA-B*4403, HLA-B*5101, HLA-B*5201, HLA-C*0702, and HLA-C*1202 alleles are relatively lower than in the Japanese population. These data may suggest that HLA-B*5901 is one of the candidate markers for CBZ-induced SJS in Japanese.

引用

页码：297 / 300

页数：4